Hepatitis C: Early Detection Means Better Health(NC)-Experts ... (Cirrhosis)

Hepatitis C: Early Detection Means Better Health(NC)-Experts ...
Blink: Hepatitis C Added by glog (NC)-Experts estimate that 240000 people in Canada are currently infected with hepatitis C, of whom only 30% know they have the virus. The only way to find out for sure if you have hepatitis C is through a blood test. ...... Read more... blink it

Primary Biliary Cirrhosis
Title: Primary Biliary CirrhosisCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

Magnetic Resonance Imaging (MRI Scan)
Title: Magnetic Resonance Imaging (MRI Scan)Category: Procedures and TestsCreated: 12/31/1997Last Editorial Review: 8/31/2005

Liver Blood Tests
Title: Liver Blood TestsCategory: Procedures and TestsCreated: 6/2/1998Last Editorial Review: 8/27/2005

Hepatitis B (Cirrhosis)

Hepatitis B
Title: Hepatitis BCategory: Diseases and ConditionsCreated: 1/26/2001 11:58:00 AMLast Editorial Review: 9/21/2005

Liver Blood Tests
Title: Liver Blood TestsCategory: Procedures and TestsCreated: 6/2/1998Last Editorial Review: 8/27/2005

Primary Biliary Cirrhosis
Title: Primary Biliary CirrhosisCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....

What is Hepatitis C?(NC)-Hepatitis C is an infectious (Cirrhosis)

What is Hepatitis C?

(NC)-Hepatitis C is an infectious virus that is carried in the blood and harms the liver. About 240,000 Canadians are infected, many of whom are unaware that they even have it. The number of people with hepatitis C is increasing in Canada and around the world, primarily among those who share needles and other drug equipment. An estimated 5,000 Canadians - mostly young people - get this virus each year. p>

Although the hepatitis C virus has been around for a long time, it was only identified in 1989. It causes inflammation of the liver, which often progresses to cirrhosis (scarring that makes it difficult for the liver to function normally). Of the estimated 5,000 people that are newly infected each year, up to 70 percent experience no symptoms. For some, symptoms may not show up for 20 or 30 years. In the meantime, they may, unknowingly, be infecting others. That is why it is important to know if you are at risk and how to take preventative action.

If you think you have hepatitis C, or that you may be at risk, visit your doctor and ask for the simple blood test for this disease. For more information, contact a health care professional, and visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services.

Treating Chronic Mutational Hepatitis B with Chinese Medicine (Cirrhosis)

Treating Chronic Mutational Hepatitis B with Chinese Medicine Vitalliver (Vigconic Suppositories)

Treating chronic mutational hepatitis B with Chinese medicine Vitalliver (Vigconic suppositories)

ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN

Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China

Research Method:

Quantitative determination by contrasting HBV-DNA of cases before and after the treatment.

Number of cases: 25 (n)

Case Selection: Between the age of 16 and 65, in accordance with the diagnosis standards pf chronic Hepatitis B, with negative e antigen and positive e antibody, HBV-DNA > 1 104 cp/mL.

Detection Method: All the blood samples are detected by Sichuan Clinical Detection Center; PCR-ELISA quantitative determination is used within detection range of 1 104 - 1 107-8, HBV-DNA, unit of measurement is cp/mL.

Direction Plan: one suppository provided by Vigconic (International) Ltd. Bid. The course of treatment is six months, the tracing observation after withdrawal lasts six months.

Observation index:

1. HBV-DNA response after the treatment.
   

2. Lasting HBV-DNA response (six months after withdrawal).
   p>

Criterion of Therapeutic Effect:

1. If HBV-DNA volume 1 104 cp/mL: 4/25 (16%)
   

2. Lasting response:
   

HBV-DNA volume 1 104 cp/mL: 2/25 (8%)

Among the results of lasting response, 16 blood serum samples are detected through fluorimetric quantitative determination PCR by the instruments of PE.USD, H-7700 in the second attached hospital of Guangzhou Medical College. The result is in accordance with that in Sichuan Clinical Testing Center. (8 cases among it 1 102 cp/mL). The testing range of this testing method is 1 102 - 1 107-8 cp/mL.

Conclusion

The reason for the repeatedly abnormal liver function of Chronic Hepatitis B (CHB) patients lies in the repeatedly duplication of HBV after infection, which leads to fibrosis of liver, then cirrhosis and liver cancer. It is commonly accepted that if CHB shows the transformation of HBeAg/Anti-HBe, HBV-DNA becoming negative, liver function returning to normal state, the disease is relieved. However, parts of patients with the transformation of HBeAg/Anti-HBe still remain positive in HBV-DNA and the pathological change in the liver continues. Because HBV-DNA occurs promoter mutation in the anterior C section (1896 necleoside G-A variation) or in the C section (1762 nucleoside T variation, 1764 G-A variation), HBeAg cannot come into being. Therefore, the HBeAg in the patient s blood cannot be detected, while the virus can keep on duplicating and fixing itself. Through sequential assay of nucleic acid, it proves that promoter mutation appears in 30%-60% of HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section. In some provinces and cities of the People of China, the percentage of promoter mutation appears in HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section is from 17.6% to 78.9%. Eight out of the 25 cases of our observation go through the sequential assay of nucleic acid carried out by the Department of Microbiology of the University of Hong Kong. It all proves to have HBV-DNA mutation. The chronic mutational Hepatitis B is infectious and apt to cause cirrhosis and liver cancer since the present medicines of antivirus and immuno-modulator do not produce the expected therapeutic effects.

Vitalliver suppository is made up from a formula of Chinese herbs, including Ginseng, Deer Horn, Cordyceps, Radix Astragali, Frudctus Cnidii, Semen Cuscutae, etc. The formula is mainly for strengthening the body resistant and primarily for reinforcing Kidney Qi, which produces good therapeutic effects in treating chronic mutational Hepatitis B. The mechanism is probably that through the regulating of immune system, the duplication of virus is inhibited and meanwhile the liver is protected, so it can produce a lasting therapeutic effect. No adverse reaction and severe accident happens during clinical observation, so it is safe for using. Vitalliver is bringing hopes to the treatment of chronic mutational Hepatitis B.

* The second stage of clinical trial would be carrying out by the Microbiology Department of the University of Hong Kong and Chengdu University of Traditional Chinese Medicine.

For more information, please visit: http://www.vigconic.com

Or, contact:

William Yip cs@vigconic.com
p>
5/F, Cheung Wah Building, Sheung Heung Rd,

Kowloon, Hong Kong

Tel: 852-27656200

Fax: 852-27645314
p>

Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China

webmaster@vigconic.com

Treating Chronic Mutational Hepatitis B with Chinese Medicine (Cirrhosis)

Treating Chronic Mutational Hepatitis B with Chinese Medicine Vitalliver (Vigconic Suppositories)

Treating chronic mutational hepatitis B with Chinese medicine Vitalliver (Vigconic suppositories)

ZHANG GUAN HUA, LIANG CHAO, ZHENG WAN PIN

Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China

Research Method:

Quantitative determination by contrasting HBV-DNA of cases before and after the treatment.

Number of cases: 25 (n)

Case Selection: Between the age of 16 and 65, in accordance with the diagnosis standards pf chronic Hepatitis B, with negative e antigen and positive e antibody, HBV-DNA > 1 104 cp/mL.

Detection Method: All the blood samples are detected by Sichuan Clinical Detection Center; PCR-ELISA quantitative determination is used within detection range of 1 104 - 1 107-8, HBV-DNA, unit of measurement is cp/mL.

Direction Plan: one suppository provided by Vigconic (International) Ltd. Bid. The course of treatment is six months, the tracing observation after withdrawal lasts six months.

Observation index:

1. HBV-DNA response after the treatment.
   

2. Lasting HBV-DNA response (six months after withdrawal).
   p>

Criterion of Therapeutic Effect:

1. If HBV-DNA volume 1 104 cp/mL: 4/25 (16%)
   

2. Lasting response:
   

HBV-DNA volume 1 104 cp/mL: 2/25 (8%)

Among the results of lasting response, 16 blood serum samples are detected through fluorimetric quantitative determination PCR by the instruments of PE.USD, H-7700 in the second attached hospital of Guangzhou Medical College. The result is in accordance with that in Sichuan Clinical Testing Center. (8 cases among it 1 102 cp/mL). The testing range of this testing method is 1 102 - 1 107-8 cp/mL.

Conclusion

The reason for the repeatedly abnormal liver function of Chronic Hepatitis B (CHB) patients lies in the repeatedly duplication of HBV after infection, which leads to fibrosis of liver, then cirrhosis and liver cancer. It is commonly accepted that if CHB shows the transformation of HBeAg/Anti-HBe, HBV-DNA becoming negative, liver function returning to normal state, the disease is relieved. However, parts of patients with the transformation of HBeAg/Anti-HBe still remain positive in HBV-DNA and the pathological change in the liver continues. Because HBV-DNA occurs promoter mutation in the anterior C section (1896 necleoside G-A variation) or in the C section (1762 nucleoside T variation, 1764 G-A variation), HBeAg cannot come into being. Therefore, the HBeAg in the patient s blood cannot be detected, while the virus can keep on duplicating and fixing itself. Through sequential assay of nucleic acid, it proves that promoter mutation appears in 30%-60% of HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section. In some provinces and cities of the People of China, the percentage of promoter mutation appears in HBeAg negative Chronic Hepatitis B (CHB) in the anterior C section or in the C section is from 17.6% to 78.9%. Eight out of the 25 cases of our observation go through the sequential assay of nucleic acid carried out by the Department of Microbiology of the University of Hong Kong. It all proves to have HBV-DNA mutation. The chronic mutational Hepatitis B is infectious and apt to cause cirrhosis and liver cancer since the present medicines of antivirus and immuno-modulator do not produce the expected therapeutic effects.

Vitalliver suppository is made up from a formula of Chinese herbs, including Ginseng, Deer Horn, Cordyceps, Radix Astragali, Frudctus Cnidii, Semen Cuscutae, etc. The formula is mainly for strengthening the body resistant and primarily for reinforcing Kidney Qi, which produces good therapeutic effects in treating chronic mutational Hepatitis B. The mechanism is probably that through the regulating of immune system, the duplication of virus is inhibited and meanwhile the liver is protected, so it can produce a lasting therapeutic effect. No adverse reaction and severe accident happens during clinical observation, so it is safe for using. Vitalliver is bringing hopes to the treatment of chronic mutational Hepatitis B.

* The second stage of clinical trial would be carrying out by the Microbiology Department of the University of Hong Kong and Chengdu University of Traditional Chinese Medicine.

For more information, please visit: http://www.vigconic.com

Or, contact:

William Yip cs@vigconic.com
p>
5/F, Cheung Wah Building, Sheung Heung Rd,

Kowloon, Hong Kong

Tel: 852-27656200

Fax: 852-27645314
p>

Chengdu University of TCM, Hepatitis Laboratory in the attached hospital of Chengdu University of TCM, Sichuan, China

webmaster@vigconic.com

Hepatitis C: Early Detection Means Better Health(NC)-Experts estimate (Cirrhosis)

Hepatitis C: Early Detection Means Better Health

(NC)-Experts estimate that 240,000 people in Canada are currently infected with hepatitis C, of whom only 30% know they have the virus. The only way to find out for sure if you have hepatitis C is through a blood test. Your doctor can order one for you. By taking this action you'll be doing yourself a favour because hepatitis C can be treated only if it has been detected. Untreated hepatitis C can lead to severe conditions that require long-term, intensive care.

For more information visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services.